Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Martini Str. 52, 20246, Hamburg, Germany.
Langenbecks Arch Surg. 2023 Oct 12;408(1):396. doi: 10.1007/s00423-023-03129-3.
With robotic surgical devices, an innovative tool has stepped into the arena of minimally invasive hernia surgery. It combines the advantages of open (low recurrence rates and ability to perform complex procedure such as transverse abdominis release) and laparoscopic surgery (low rate of wound and mesh infections, less pain). However, a superiority to standard minimally invasive procedures has not yet been proven. We present our first experiences of robotic mesh repair of incisional hernias and a comparison of our results with open and minimally invasive sublay techniques.
A retrospective analysis of all patients who underwent robotic-assisted mesh repair (RAHR) for incisional hernia between April and November 2022 (RAHR group) and patients who underwent open sublay (Sublay group) or eMILOS hernia repair (eMILOS group) between January 2018 and November 2022 was carried out. Patients in the RAHR group were matched 1:2 to patients in the Sublay group by propensity score matching. Patient demographics, preoperative hernia characteristics and cause of hernia, intraoperative variables, and postoperative outcomes were evaluated. Furthermore, a subgroup analysis of only midline hernia was performed.
A total of 21 patients received robotic-assisted incisional hernia repair. Procedures performed included robotic retro-muscular hernia repair (r-RMHR, 76%), with transverse abdominis release in 56% of the cases. In one patient, r-RHMR was combined with robotic inguinal hernia repair. Two patients (10%) were operated with total extraperitoneal technique (eTEP). Robotic-assisted transabdominal preperitoneal hernia repair (r-TAPP) was performed in three patients (14%). Median (range) operating time in the RAHR group was significantly longer than in the sublay and eMILOS group (291 (122-311) vs. 109.5 (48-270) min vs. 123 (100-192) min, respectively, p < 0.001). The meshes applied in the RAHR group were significantly compared to the sublay (mean (SD) 529 ± 311 cm vs. 356 ± 231, p = 0.037), but without a difference compared to the eMILOS group (mean (SD) 596 ± 266 cm). Median (range) length of hospital stay in the RAHR group was significantly shorter compared to the Sublay group (3 (2-7) vs. 5 (1-9) days, p = 0.032), but not significantly different to the eMILOS group. In short term follow-up, no hernia recurrence was observed in the RAHR and eMILOS group, with 9% in the Sublay group. The subgroup analysis of midline hernia revealed very similar results.
Our data show a promising outcome after robotic-assisted incisional hernia repair, but no superiority compared to the eMILOS technique. However, RAHR is a promising technique especially for complex hernia in patients with relevant risk factors, especially immunosuppression. Longer follow-up times are needed to accurately assess recurrence rates, and large prospective trials are needed to show superiority of robotic compared to standard open and minimally invasive hernia repair.
随着机器人手术器械的出现,一种创新工具已经进入了微创疝手术领域。它结合了开放式手术(复发率低,能够进行横腹肌释放等复杂手术)和腹腔镜手术(伤口和网片感染率低,疼痛少)的优点。然而,其与标准微创手术相比的优越性尚未得到证实。我们介绍了首例机器人网片修补切口疝的经验,并将我们的结果与开放式和微创下修补技术进行了比较。
对 2022 年 4 月至 11 月期间接受机器人辅助网片修补术(RAHR 组)和 2018 年 1 月至 11 月期间接受开放式下修补术(Sublay 组)或 eMILOS 疝修补术(eMILOS 组)的所有切口疝患者进行了回顾性分析。RAHR 组的患者通过倾向评分匹配按 1:2 与 Sublay 组的患者匹配。评估患者的人口统计学特征、术前疝特征和疝发生原因、术中变量和术后结果。此外,还对仅中线疝进行了亚组分析。
共 21 例患者接受了机器人辅助切口疝修补术。手术包括机器人后肌疝修补术(r-RMHR,76%),56%的病例中进行了横腹肌释放。1 例患者行 r-RHMR 联合机器人腹股沟疝修补术。2 例(10%)患者采用完全腹膜外技术(eTEP)。3 例(14%)患者行机器人经腹腹膜前疝修补术(r-TAPP)。RAHR 组的中位(范围)手术时间明显长于 Sublay 和 eMILOS 组(291(122-311)比 109.5(48-270)比 123(100-192)min,p<0.001)。RAHR 组应用的网片明显大于 Sublay 组(平均(SD)529±311cm 比 356±231cm,p=0.037),但与 eMILOS 组无差异(平均(SD)596±266cm)。RAHR 组的中位(范围)住院时间明显短于 Sublay 组(3(2-7)比 5(1-9)天,p=0.032),但与 eMILOS 组无差异。在短期随访中,RAHR 和 eMILOS 组均未观察到疝复发,Sublay 组有 9%的患者复发。中线疝的亚组分析结果非常相似。
我们的数据显示机器人辅助切口疝修补术后有良好的效果,但与 eMILOS 技术相比无优势。然而,RAHR 是一种很有前途的技术,特别是对有相关危险因素的复杂疝患者,特别是免疫抑制患者。需要更长的随访时间来准确评估复发率,需要进行大型前瞻性试验以显示机器人与标准开放和微创疝修补术相比的优势。